액체생검 바이오마커 시장 - 전략적 인사이트와 예측(2026-2035년)

The Liquid Biopsy Biomarkers Market is expected to grow at a CAGR of 12.0% from a market value of USD 9.33 billion in 2026 to USD 25.81 billion in 2035.

The liquid biopsy biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision oncology, the growing demand for minimally invasive diagnostic approaches, and the expanding clinical utility of circulating molecular signatures. The market's evolution is characterized by the recognition that liquid biopsy biomarkers, including circulating tumor DNA, circulating tumor cells, cell-free DNA, and cell-free RNA, enable comprehensive genomic profiling through repeated sample collection, making longitudinal molecular monitoring feasible across multiple cancer types. The convergence of advanced sequencing technologies, digital PCR, and artificial intelligence is enabling detection of extremely low-frequency genomic alterations with increasing sensitivity and specificity. Healthcare systems are integrating liquid biopsy testing into multidisciplinary cancer care alongside conventional pathology as precision oncology increasingly depends on genomic biomarkers that identify actionable mutations, resistance mechanisms, and evolving tumor heterogeneity. Pharmaceutical companies are incorporating liquid biopsy biomarkers into clinical trials because biomarker-guided patient selection improves enrollment efficiency while increasing the probability of demonstrating therapeutic benefit in genetically defined populations. The market is witnessing significant investment in multi-cancer early detection, minimal residual disease monitoring, and companion diagnostic development, positioning liquid biopsy biomarkers as a critical component of precision oncology and longitudinal cancer management.

Market Drivers

• The expansion of precision oncology represents the primary driver for the liquid biopsy biomarkers market. Precision oncology relies on molecular biomarkers to match patients with targeted therapies based on tumor-specific genomic alterations. Demand is increasing because oncology treatment algorithms increasingly require biomarker confirmation before therapy initiation. Tissue availability remains limited in many clinical settings, creating dependence on minimally invasive biomarker testing. Diagnostic developers are expanding high-sensitivity assays that support repeated genomic assessment throughout treatment. This transition strengthens long-term demand for liquid biopsy biomarkers across both clinical practice and pharmaceutical development, resulting in sustained growth in liquid biopsy biomarker utilization. Minimal residual disease monitoring is further accelerating market growth through expanded clinical utility. MRD assessment identifies residual malignant cells that remain undetectable using conventional imaging. Clinical practice increasingly recognizes molecular recurrence before radiographic evidence emerges because earlier intervention may improve treatment planning. Healthcare providers are incorporating ctDNA-based monitoring into post-treatment surveillance protocols where clinical evidence supports implementation. Diagnostic companies continue validating highly sensitive assays capable of detecting extremely low variant allele frequencies. This evolution broadens biomarker utilization beyond initial diagnosis into long-term patient management. Companion diagnostics continue strengthening commercial demand through pharmaceutical-diagnostic collaboration. Targeted oncology drugs increasingly require validated companion diagnostics to identify eligible patients. Pharmaceutical companies are integrating biomarker testing throughout clinical development because genetically selected populations improve therapeutic response rates. Regulatory authorities continue evaluating co-development strategies that align diagnostic approval with therapeutic authorization. Diagnostic manufacturers are strengthening collaborations with pharmaceutical sponsors to accelerate commercialization. Next-generation sequencing continues improving analytical performance and expanding clinical applications. Sequencing technologies enable comprehensive genomic profiling from limited circulating nucleic acids.

Market Restraints

• Limited analytical standardization across laboratories continues creating variability in clinical interpretation and cross-platform result comparability. The lack of harmonized protocols reduces clinical confidence and comparability. Reimbursement remains inconsistent across healthcare systems because many emerging biomarker applications still require stronger evidence demonstrating long-term clinical utility. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Early-stage cancers frequently release low concentrations of circulating tumor material, reducing biomarker sensitivity in certain patient populations. The biological limitations of circulating biomarkers create challenges for early detection. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

• The technology landscape is characterized by the growing importance of integrated multi-omics platforms, AI-enabled interpretation, and highly sensitive detection methods. ctDNA represents the leading biomarker segment because it provides tumor-specific genomic information through minimally invasive blood sampling. Clinical demand is increasing as oncologists require repeated molecular profiling throughout treatment selection and disease monitoring. Detection sensitivity remains a critical constraint because early-stage disease releases limited circulating DNA into the bloodstream. Diagnostic developers are improving sequencing chemistry and bioinformatics pipelines to detect increasingly lower variant allele frequencies. NGS enables comprehensive genomic profiling from limited circulating nucleic acids. PCR remains important for focused mutation detection where rapid turnaround is prioritized. Immunoassays continue supporting specific protein biomarker detection. The segment analysis reveals that blood remains the dominant sample type because collection procedures integrate easily into routine clinical workflows while enabling repeated longitudinal assessment. Demand is increasing as healthcare providers seek alternatives to invasive tissue biopsy, particularly when repeated sampling becomes clinically necessary. MRD monitoring represents one of the fastest-evolving clinical applications because residual cancer cells frequently remain undetectable through conventional imaging. Demand is increasing as clinicians seek earlier molecular evidence of recurrence following surgery or systemic therapy. Lung cancer, breast cancer, colorectal cancer, and prostate cancer represent significant applications. Diagnostic laboratories represent the leading end-user segment, with hospitals and academic research institutes expanding testing capabilities. The integration of AI is becoming increasingly important because AI is supporting variant classification, pattern recognition, and predictive modeling across increasingly complex biomarker datasets.

Competitive and Strategic Outlook

• The competitive landscape features specialized liquid biopsy and precision oncology companies alongside established diagnostics and life science providers. Guardant Health distinguishes itself through its exclusive focus on blood-based precision oncology diagnostics and its leadership in ctDNA technologies, building a comprehensive portfolio supporting comprehensive genomic profiling, treatment selection, recurrence monitoring, and cancer screening. Natera has established strategic differentiation through its personalized minimal residual disease platform, leveraging individualized tumor-informed assays rather than fixed genomic panels to enable highly sensitive monitoring of residual disease following surgery and systemic treatment. Exact Sciences differentiates itself by combining molecular diagnostics, cancer screening, and precision oncology into an integrated oncology portfolio, emphasizing earlier cancer detection while expanding genomic testing capabilities across disease management pathways. Roche maintains a strategically distinct position by integrating pharmaceutical development with one of the world's largest in vitro diagnostics businesses, enabling simultaneous development of targeted therapies and companion diagnostics. QIAGEN differentiates itself through its extensive molecular diagnostics portfolio spanning sample preparation, assay development, sequencing technologies, and bioinformatics solutions. NeoGenomics has established competitive strength through comprehensive oncology laboratory services integrating molecular diagnostics, pathology, cytogenetics, and genomic profiling. Companies are pursuing product portfolio expansion through innovation in ctDNA assays, MRD platforms, and multi-cancer early detection tests. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include Volition saying its Capture-Seq liquid biopsy workflow can generate cancer-derived plasma DNA sequence sets with more than 99% purity, intended to improve signal quality in cancer detection. Memorial Sloan Kettering highlighted a liquid biopsy approach that uses AI and nanosensors to detect brain tumors and potentially distinguish among cancer types. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The liquid biopsy biomarkers market is positioned for sustained growth driven by the convergence of precision oncology, technological innovation, and expanding clinical applications. The transition from episodic tissue-based evaluation toward continuous molecular assessment represents a fundamental shift in cancer management. While challenges related to standardization, reimbursement, and sensitivity persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with liquid biopsy biomarkers evolving into a foundational component of precision oncology, supporting early detection, treatment selection, therapeutic monitoring, and recurrence surveillance across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Liquid Biopsy Biomarkers Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Biomarker Landscape Overview
• 3.8 Cancer Burden and Clinical Need for Liquid Biopsy Biomarkers
• 3.9 Biomarker Discovery and Validation Landscape
• 3.10 Clinical Utility Across the Patient Care Continuum
• 3.11 Companion Diagnostics and Precision Oncology Integration
• 3.12 Testing Volume Analysis
• 3.13 Patient Population and Biomarker Adoption Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Multi-Omics Integration in Liquid Biopsy Biomarker Development
• 6.6 Artificial Intelligence and Bioinformatics Integration
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Liquid Biopsy Biomarkers Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Sample Type
• 8.3 Analysis by Technology Platform
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Cancer Type
• 8.6 Analysis by Testing Purpose

9. Global Liquid Biopsy Biomarkers Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Circulating Tumor DNA (ctDNA)
  • 9.1.2 Circulating Tumor Cells (CTCs)
  • 9.1.3 Cell-Free DNA (cfDNA)
  • 9.1.4 Cell-Free RNA (cfRNA)
  • 9.1.5 Other Biomarkers
• 9.2 By Sample Type
  • 9.2.1 Blood
  • 9.2.2 Urine
  • 9.2.3 Cerebrospinal Fluid (CSF)
  • 9.2.4 Saliva
  • 9.2.5 Other Body Fluids
• 9.3 By Technology Platform
  • 9.3.1 Next-Generation Sequencing (NGS)
  • 9.3.2 Polymerase Chain Reaction (PCR)
  • 9.3.3 Immunoassays
  • 9.3.4 Other Molecular Technologies
• 9.4 By Clinical Application
  • 9.4.1 Early Cancer Detection & Screening
  • 9.4.2 Companion Diagnostics
  • 9.4.3 Treatment Response Monitoring
  • 9.4.4 Minimal Residual Disease (MRD) Monitoring
  • 9.4.5 Disease Recurrence Monitoring & Prognostic Assessment
• 9.5 By Cancer Type
  • 9.5.1 Lung Cancer
  • 9.5.2 Breast Cancer
  • 9.5.3 Colorectal Cancer
  • 9.5.4 Prostate Cancer
  • 9.5.5 Ovarian Cancer
  • 9.5.6 Pancreatic Cancer
  • 9.5.7 Liver Cancer
  • 9.5.8 Other Cancers
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Academic & Research Institutes
  • 9.6.4 Others

10. Global Liquid Biopsy Biomarkers Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Liquid Biopsy Biomarkers Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Japan
• 11.10 China
• 11.11 South Korea
• 11.12 India
• 11.13 Australia
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Guardant Health, Inc.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Natera, Inc.
• 13.3 Exact Sciences Corporation
• 13.4 Illumina, Inc.
• 13.5 QIAGEN N.V.
• 13.6 Bio-Rad Laboratories, Inc.
• 13.7 F. Hoffmann-La Roche Ltd.
• 13.8 NeoGenomics, Inc.
• 13.9 Exact Sciences Corporation
• 13.10 Myriad Genetics, Inc.

14. Global Liquid Biopsy Biomarkers Market Commercial Forecast Analysis

• 14.1 Commercial Forecast by Biomarker Type
• 14.2 Commercial Forecast by Technology Platform
• 14.3 Commercial Forecast by Clinical Application
• 14.4 Commercial Forecast by Cancer Type
• 14.5 Commercial Forecast by End User

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends